# ENJAYMO - **Website:** - **Primary alias:** `enjaymo.com` ## Description ENJAYMO is an innovative, chemotherapy-free therapy designed to address red blood cell destruction, specifically in patients suffering from cold agglutinin disease (CAD). Marketed under the brand name ENJAYMO® (sutimlimab-jome), this prescription medication has demonstrated efficacy in clinical trials, with 73% of patients achieving significant improvements in hemoglobin levels compared to only 15% in the placebo group. By preventing hemolysis, ENJAYMO not only enhances hemoglobin stability but also promotes transfusion-free survival, with 82% of users remaining transfusion-free over a 26-week period. The brand focuses on supporting individuals with CAD through patient-centered resources, offering tools and guidance on medication use, dosing, and potential side effects. ENJAYMO aims to alleviate the debilitating effects of this rare illness, including fatigue, as evidenced by a notable average improvement in patient-reported fatigue scores. With a commitment to safety and effectiveness, ENJAYMO strives to improve the quality of life for adults affected by CAD, while ongoing support resources help guide patients through their treatment journey. ## Industries - ⛑ Health - ⛑ Biotechnology and Pharmaceuticals _(under Health)_ ## Links - [facebook](https://facebook.com/EnjaymoRx) ## Logos & icons - logo _(primary)_ — PNG, SVG — [download](https://cdn.brandfetch.io/idlNzLO6_m/w/820/h/378/theme/dark/logo.png?c=1bxid64Mup7aczewSAYMX&t=1786398914476) - icon _(primary)_ — JPEG — [download](https://cdn.brandfetch.io/idlNzLO6_m/w/1000/h/1000/theme/dark/icon.jpeg?c=1bxid64Mup7aczewSAYMX&t=1786398914704) ## Colors | Name | Hex | Theme | | --- | --- | --- | | Astral | #338199 | accent | | Orient | #00607f | dark | | White | #ffffff | light | ## Fonts - din-2014 — asset _(custom)_ --- _Source: _ _See [/llms.txt](/llms.txt) for a full list of agent-readable pages, and [/auth.md](/auth.md) for how agents authenticate._